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SUMMARY 
   Human papillomavirus (HPV) infections cause cervical cancer and premalignant dysplasia.  Data on 
HPV and cervical cancer in Kenya are scarce.  Type-specific HPV prevalence data provides a basis for 
assessing the impact of HPV vaccination programs on cervical cytology and how HPV based screening will 
influence cervical cancer prevention.  To investigate HPV infections in a population in Kenya, we obtained 
cervical cells specimen from 498 women in a population in Thika district.  We report HPV type specific 
prevalence and distribution data for 498 women (age range 18-74 years; mean age 36 years) recruited into 
the study in relation to age and cervical cytology.  The study was conducted between January to May 
2010.  Pap smears were performed, HR HPV DNA were detected by Digene Hybrid capture 2® (hc2) test 
and HPV genotyping was performed with Multiplex Luminex HPV genotyping kit (Multimetrix, Progen, 
Germany).  Samples from 106 women (21.3%) tested positive for HPV.  Multiple HPV types were detected 
in 40 (37.7% of HC2-positive samples) and the rest had infection with single HPV type.  The most common 
HR HPV type at all ages was HPV16, 52, 56, 66, and 18. There was a marked decline in the prevalence of 
HR-HPV with age.   
   The pattern of HR HPV distribution in this population was slightly different from existing literature, 
which has important consequences for HPV vaccination and prevention programs. 
 
 
[Afr J Health Sci. 2011; 19:53-62] 
 
Introduction 
   Human papillomavirus (HPV) infection has been 
recognized as the central causal agent cervical 
cancer which is the second most neoplastic 
malignancy of women worldwide [1].  More than 
100 HPV types have been described and 40 can 
infect the anogenital tract [2].  Genital HPV types 
are categorized according to their association with 
cervical cancer [1].  About 20 are classified as high 
risk HPV (HR HPV) and are associated with 
cervical cancer and precancerous lesions, as well as 
low grade cervical pathology [3].  Low risk HPV 
(LR HPV) cause low grade cervical lesions, genital 
warts and recurrent respiratory papillomatosis [3].   
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Worldwide, HPV types 16 and 18 are responsible 
for approximately 70% of cervical cancer cases; 
HPV types 31, 33, 35, 42, 52 and 58 account for an 
approximately 20% of the cases [4].  However, 
there is substantial geographical variation in the 
relative frequency of different HR HPV types [4].   
   These findings have led to the development of 
two vaccines against HR HPV.  A quadrivalent 
prophylactic vaccine against HPV types 6, 11, 16 
and 18 was licensed in the USA [5] and more recent 
a bivalent vaccine against HPV 16 and 18 [6]. 
While commercial vaccines against HPV 16 and 
HPV 18 are now available, global variations in 
HPV type specific prevalence could affect their 
regional effectiveness [7]. Despite the widespread 
efforts to ascertain the burden of HPV infections in 
populations across diverse regions, little systematic 
data are available on the prevalence of HPV 
infections in Kenyan population.   
   The most prevalent type worldwide is HPV 16, 
and there is less variation in the geographical 
distribution of HPV 16 than in that of the other 
types [8].  The prevalence of HPV is higher in 
African women with a normal cervical cytology 
than in women in other regions of the world [4].  
Yet, HPV 16 infections of women with a normal 
cytology are found more commonly than infections 
caused by other HPV types in regions of the world 
apart from sub-Saharan Africa, where infections by 
other oncogenic types, most significantly, HPV 35, 
may dominate [4].  Indeed, the latter study also 
showed that HPV 35 was as common in Africa as 
HPV 16 (in 8% of infections), followed by HPV 31, 
HPV 45, HPV 56, and HPV 58 (in 6% of infections) 
[4].  HPV testing rather than cytology test has been 
recommended for cervical cancer screening in some 
resource poor areas [9] and in areas with high 
prevalence of Human Immunodeficiency virus 
(HIV) [10].  
   Kenya has a population of 10.32 millions women 
ages 15 years and older who are at risk of accruing 
HPV infections and developing cervical cancer 
[11].  Current estimates indicate that every year 
2635 new cases of cervical cancer are reported and 
2111 deaths from the disease [12].  Cervical cancer 
ranks as the 1st most frequent cancer among women 
in Kenya, and the 2nd most frequent cancer among 
women between 15 and 44 years of age [11].  About 
38.8% of women in the general population are 
estimated to harbour cervical HPV infection at a 
given time, and 60.9% of invasive cervical cancers 
are attributed to HPV 16 or HPV18 [12].  In Kenya, 
a clinic based study found the prevalence of HPV in 
HIV positive women was found to be 49% and 17% 
in HIV negative women ([13].  This is similar to 
previous findings of a clinic based study, HPV 
prevalence of 41% in HIV positive women and 14% 
in HIV negative women [14].  
  Vaccination for the primary prevention of Human 
Papillomavirus infection in adolescent girls and use 
of methods to detect infection with carcinogenic 
HPV types allowing for early detection and 
treatment of precancerous cervical lesions are the 
main approaches of dealing with cervical cancer in 
recent years in the developed countries [15].  In 
Kenya there have been relatively few population 
based studies on the distribution of HPV genotypes.  
The recent and only available data in Kenya on 
HPV genotypes distribution is from a study in 2002 
by Globoscan [12].  To address this lack of data, we 
examined HPV genotype distribution in 498 women 
who were between ages 18 and 74 who participated 
in the study. The findings report the type specific 
prevalence data for all HR HPV types in the 
population. 
 
Materials and methods 
  The study was conducted in Thika District.  A total 
of 498 samples were collected. Thika district is one 
of the administrative districts in Central province 
with the capital being Thika Town. The district is 
quite densely populated with a population of about 
700,000 covering an area of 1960.2 sq km2. The 
population is both rural and urban and it’s highly 
cosmopolitan. It is one of the leading industrial 
districts in the country as well as rich agricultural 
district. The poverty incidence is reported at 48.8%. 
The form of poverty include food and absolute 
poverty and are on the increase due to factors such 
as unemployment, collapse of agricultural centers 
and industries, poor infrastructure and the rise of 
HIV/AIDS. The total population at risk of 
developing cervical cancer is approximately 
300,000 as per the population projections for 2010 
[16].  
  Women who live in this region were invited 
through churches, posters placed at markets places 
and health centers to participate in the study. 
Sensitization meetings were held with the local 
doctors, public health officers, church leaders and 
local administration officers and this team was used 
to inform and request the communities to participate 
in the study. We also put up posters in the local 
shopping centers and local health centers and 
colleges. The local administration officers through 
the public health office were also requested to ask 
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the community to attend the screening and 
participate in the study.  
  Women were eligible for the study if they were (a) 
self identified as residing in the region; (b) were 
ages 18 and above (c) had an intact uterus an no 
current referral for a hysterectomy (d) Did not 
report the use of vaginal medication for the previous 
two days (e) did not report treatment for cervical 
disease for the previous 6 months and were not 
pregnant at the time of study. Ethical approval was 
obtained from the National Ethical Review 
Committee at the Kenya Medical Research Institute. 
The moderators explained to the participants the 
purpose of the research, detailed explanation of the 
procedures involved and assured them of 
confidentiality.  Those who agreed to participate 
signed the informed consent forms.  All the clinical 
examinations were conducted by female nurses and 
privacy was observed in all cases.  Those who were 
found to have any symptoms of vaginal infection 
during the cervical examination and sample 
collection were referred to clinical officer in the 
reproductive health clinic for further examination 
and treatment.  A semi structured questionnaire 
collected information on sociodemographic 




  Cervical cells were collected from the participants 
during the gynecology examination. The samples 
were collected using the ThinPrep® Pap test Kit as 
per the manufacturer’s instruction and stored in the 
PreservCyt solution vial (Hologic, Bedford, USA).  
Once the samples were collected they were all 
transported in room temperature to the institute of 
pathology, university of Heidelberg for analysis. 
 
High risk Human papillomavirus detection 
  After processing for cytology, residual ThinPrep® 
liquid based cytology samples four mls of the 
sample was used for HR HPV detection for all the 
samples. The HR HPV detection was carried out 
using the Digene Hybrid capture 2® (hc2) test 
according to the manufacturer’s instructions as 
described previously [17].  A positive hc2 result 
was defined as RLU/Co  1, according to the 
manufacturer’s criteria.  Digene Hybrid capture 2® 
(hc2) test detects HR HPV types 
16/18/31/33/35/39/45/51/52/56/58/59/68 and 5 low-
risk types 6/11/42/43/44. 
 
Human papillomavirus Polymerase chain 
reaction (PCR) and genotyping 
  HPV genotyping was performed on all samples 
that were positive in Digene Hybrid capture 2® 
(hc2) test.  DNA was extracted from 2 ml of the 
PreservCyt sample solution using the Genfind™ 
DNA extraction kit as per the manufacturer’s 
instructions.  All reagents were equilibrated to room 
temperature prior to use and all prepared reaction 
mixtures were not stored for later use.10 mM Tris, 
pH 7.5, solution from a 2M Tris stock solution was 
prepared.  The Lysis Buffer and Proteinase K (96 
g/mL) in an appropriate-sized conical tube was 
combined as per number of samples and mix by 
pipetting up and down.  The extracted DNA was 
stored at -20 C.  
  HPV genotyping was done using Multiplex.  A 10 
µl volume of extracted DNA was added to an equal 
volume of reaction mixture containing 2µl primer 
set 1, 0.5µl primer set 2, 5µl PCR gold buffer, 7µl 
of 25Mm MgCL2, 7µl DNTP mix (10mM each) 
and 0.2µl DNA polymerase (5 U/ µl).  PCR grade 
water was added to 40 µl per sample. The PCR 
tubes were then placed in a thermocycler with the 
following protocol: 94C for 15 minutes, (94C for 
20 seconds, 38C for 40 seconds, 71C for 80 
seconds) * 40, and 71C for 4 minutes.   
  Genotyping was performed using a Multiplex HPV 
genotyping kit (Multimetrix, Progen, Germany) as 
per the manufacturer’s instructions. Each 200ng 
DNA was subjected to PCR using HPV consensus 
primers for amplification of the HPV L1 gene.  
Amplified DNA was genotyped by applying a bead 
based hybridization with HPV type-specific probes 
using the Luminex technology, allowing for typing 
of the high risk types HPV16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 66, 68, 70, 73, and 82.  PCR 
primers and Luminex reagents are both used from 
the Multimetrix HPV genotyping kit (Progen, 
Heidelberg).  Two sets of primers are provided by 
the manufacturer. Primer set 1 contained all HPV 
primers: 9 forward and 3 biotinylated reverse 
primers necessary to amplify the HPV types under 
investigation. Primer set 2 (DNA quality control 
primers) contained primers for the amplification of 
a -globin gene fragment which were included in 
each run to ensure sufficient DNA integrity.  After 
resuspending the beads, the read-out in the Luminex 
analyzer was performed. HPV types are discerned 
according to the unique bead signature, whereas the 
presence of PCR products is determined by 
phycoerythrin fluorescence. An analytical 
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sensitivity cut-off was calculated based on the 
negative control.  
 
Cytology 
  All cytology was read independently of the HPV 
results at the Institute of Pathology, Mannheim. 
Slides were read according to the routine laboratory 
protocol and reported as such.  National guidelines 
were adhered to, thus high grade abnormalities were 
referred for colposcopy and biopsy.  In women with 
low grade abnormalities cytology was to be 
repeated at 6 months. 
 
Data analysis 
  All the data collected was double entered into a 
computer database designed using MS-Access 
application.  Back up was performed regularly to 
avoid any loss or tampering of data.  Data cleaning 
and validation was performed to achieve a clean set 
that was exported to a Statistical Package for Social 
Sciences (SPSS) 12.0 file.  Hard cover books were 
used to document any vital information collected 
and observed during the study period. All the filled 
questionnaires and tapes were arranged in box files 
and properly stored in lockable drawers for 
confidentiality.Univariate analysis was performed.  
All variables were subjected to descriptive data 
analysis.  Descriptive statistics such as median, 
minimum, and maximum was used to summarize 
continuous variables while categorical variables 
was summarized using proportions 
 
Results 
Characteristics of the study population 
  A total of 498 women met the eligibility criteria.  
Mean age of the study participants was 36 + 10 
ranging between 18 and 74 years. Distribution of 
age among the participants revealed comparable 
proportions in every category. The highest 
proportion seen in those aged 30 - 34 years (18.1%; 
90) followed by 35 - 39 years (17.5%; 87).  The 
lowest proportion observed (9.2%; 46) was 45 - 49 
years old.  The mean number of full term births for 
those that had given birth to at least one child was 3 
+ 1 ranging between 0 and 10 children.  The highest 
proportion (62.2%; 310) of the participants had 1 – 
3 children with 18.9% (95) having more than three. 
A significant majority (66.9%; 333) of the study 
participants was single.  Level of education varied 
between none and university education, with a very 
small proportion (1.0%; 5) having no formal 
education.  The highest proportion of participants 
(37.1%; 185) had secondary education.  Source of 
income among the study participants was 
characterized by high self employment (39.4%; 
196) and formal employment (30.9%; 154).  Level 
of unemployment was relatively high (23.3%; 116) 
while 5.2% (26) of the participants being 
students/housewife.  Six of the participants (1.2%) 
declined to mention their source of income. 
  A total of 498 women were tested using Digene 
(hc2) procedure at recruitment.  Samples from 106 
women (21.3%) tested positive for HPV.  Out of all 
the samples that were analyzed 22 were classified as 
HC2-positive but HPV negative. The remaining 103 
HC2-positive samples (82.4%) were positive for 
one or more of the 24 HPV types.  Multiple HPV 
types were detected in 40 (37.7% of HC2-positive 
samples) and infection with single HPV type was 
detected in 63 (59.4%) of the HC2-positive 
samples.  Most women had normal cytology (89%), 
(3%) had LSIL, (5.8%) ASCUS and (2.2%) had 
HSIL. 
  The prevalence rates for specific HPV type are 
shown in Table 1, overall and by age group.  The 
most common HPV type at all ages was HPV16 
(overall prevalence 4.6%), followed by HPV52 
(overall prevalence 3.8%), HPV56 and HPV66 
(both 2.4%), HPV18 and HPV35 (both 2.0%), 
HPV51 (1.8%), HPV42, HPV68 and HPV73 (all 
three at 1.6% each), HPV6 and HPV45 (both1.4%), 
HPV11 and HPV59 (both 1.2%), HPV31 and 
HPV53 (both 1.0%).  There was a marked decline 
in the prevalence of HPV with age, both overall 
(28.1% below age 30 years and 17.4% at 30 years 
or above) (Table 1). 
  A total of 498 women were tested using Digene 
(HC2) procedure at recruitment.  Samples from 106 
women (21.3%) tested positive for HPV.  Out of all 
the samples that were analyzed 22 were classified as 
HC2-positive but HR-HPV negative. The remaining 
103 HC2-positive samples (82.4%) were positive 
for one or more of the 24 HR types.  Multiple HPV 
types were detected in 40 (37.7% of hc2-positive 
samples) and infection with single HPV type was 
detected in 63 (59.4%) of the hc2-positive samples.  
Most women had normal cytology 443 (89%), 15 
(3%) had LSIL, 28 (5.8%) ASCUS and 11 (2.2%) 
had HSIL. 
  The prevalence rates for specific HPV type are 
shown in Table 1, overall and by age group.  The 
most common HPV type at all ages was HPV16 
(overall prevalence 4.6%), followed by HPV52 
(overall prevalence 3.8%), HPV56 and HPV66 
(both 2.4%), HPV18 and HPV35 (both 2.0%), 
HPV51 (1.8%), HPV42, HPV68 and HPV73 (all 
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three at 1.6% each), HPV6 and HPV45 (both1.4%), 
HPV11 and HPV59 (both 1.2%), HPV31 and 
HPV53 (both 1.0%).   
  There was a marked decline in the prevalence of 
HPV with age, both overall (28.1% below age 30 
years and 17.4% at 30 years or above) (Table 1).  
Similarly, there was a marked decline in the 
prevalence of HPV with CIN status, both overall 
(81.8% of women who tested positive for any type 
of CIN and 19.3% of those who tested negative i.e. 
normal) and for each HPV type (Table 2). 
  The overall HPV prevalence in women with 
normal cytology was 78(17.6%), ASCUS 5(10.3%), 
LSIL 11(73.3%) and with HSIL 9(81.3%) as shown 
in Table 2.   HPV 16 was most common amongst 
the ASCUS and HSIL cytology groups. In LSIL 
cytology group HPV 42, 52 and 56 were the most 
prevalent while in those with normal cytology, HPV 









<= 29 years 30 - 39 years 40 - 49 years 50 or more years All ages 
 HR-HPV type n 
% of all 
women 
% of  
HR-HPV + 
women  n 
% of all 
women 
% of  
HR-HPV + 
women  n 




women  n 
% of all 
women 
 % of  
HR-HPV + 
women n 
% of all 
women 
 % of  
HR-HPV + 
women 
6 5 3.3 11.6 2 1.1 5.6 0 0.0 0.0 0 0.0 0.0 7 1.4 6.8 
11 3 2.0 7.0 1 0.6 2.8 2 1.7 12.5 0 0.0 0.0 6 1.2 5.8 
16 9 5.9 20.9 9 5.1 25.0 2 1.7 12.5 3 5.8 37.5 23 4.6 22.3 
18 3 2.0 7.0 3 1.7 8.3 2 1.7 12.5 2 3.8 25.0 10 2.0 9.7 
26 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 
31 2 1.3 4.7 2 1.1 5.6 1 0.9 6.3 0 0.0 0.0 5 1.0 4.9 
33 0 0.0 0.0 1 0.6 2.8 0 0.0 0.0 0 0.0 0.0 1 0.2 1.0 
35 5 3.3 11.6 4 2.3 11.1 1 0.9 6.3 0 0.0 0.0 10 2.0 9.7 
39 1 0.7 2.3 1 0.6 2.8 0 0.0 0.0 1 1.9 12.5 3 0.6 2.9 
42 4 2.6 9.3 3 1.7 8.3 1 0.9 6.3 0 0.0 0.0 8 1.6 7.8 
43 2 1.3 4.7 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 2 0.4 1.9 
44 1 0.7 2.3 2 1.1 5.6 1 0.9 6.3 0 0.0 0.0 4 0.8 3.9 
45 2 1.3 4.7 3 1.7 8.3 2 1.7 12.5 0 0.0 0.0 7 1.4 6.8 
51 2 1.3 4.7 6 3.4 16.7 0 0.0 0.0 1 1.9 12.5 9 1.8 8.7 
52 11 7.2 25.6 5 2.8 13.9 3 2.6 18.8 0 0.0 0.0 19 3.8 18.4 
53 2 1.3 4.7 2 1.1 5.6 1 0.9 6.3 0 0.0 0.0 5 1.0 4.9 
56 7 4.6 16.3 3 1.7 8.3 2 1.7 12.5 0 0.0 0.0 12 2.4 11.7 
58 1 0.7 2.3 0 0.0 0.0 0 0.0 0.0 1 1.9 12.5 2 0.4 1.9 
59 1 0.7 2.3 4 2.3 11.1 1 0.9 6.3 0 0.0 0.0 6 1.2 5.8 
66 8 5.2 18.6 2 1.1 5.6 2 1.7 12.5 0 0.0 0.0 12 2.4 11.7 
68 3 2.0 7.0 2 1.1 5.6 2 1.7 12.5 1 1.9 12.5 8 1.6 7.8 
70 1 0.7 2.3 1 0.6 2.8 1 0.9 6.3 0 0.0 0.0 3 0.6 2.9 
73 4 2.6 9.3 4 2.3 11.1 0 0.0 0.0 0 0.0 0.0 8 1.6 7.8 
82 0 0.0 0.0 2 1.1 5.6 2 1.7 12.5 0 0.0 0.0 4 0.8 3.9 
16 and/or 18 12 7.8 27.9 10 5.6 27.8 4 3.4 25.0 5 9.6 62.5 31 6.2 30.1 
Any HR-HPV 43 28.1 100 36 20.3 100 16 13.8 100 8 15.4 100 103 20.7 100 
HC2+ No HR-
HPV 11 7.2 - 7 4.0 - 3 2.6 - 1 1.9 - 22 4.4 - 
HC2 - 110 71.9 - 139 78.5 - 98 84.5 - 45 86.5 - 392 78.7 - 
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ASCUS LSIL HSIL Normal All Pap test Diagnosis 
HR-HPV 
type n 
% of all 
women 
% of all HR-
HPV+ women n 
% of all 
women 
% of all HR-
HPV+ 
women n 
% of all 
women 
% of all HR-
HPV+ 
women n 
% of all 
women 
% of all HR-
HPV+ 
women n 
% of all 
women 
% of all HR-
HPV+ 
women 
6 0 0.0 0.0 1 6.7 9.1 0 0.0 0.0 6 1.4 7.7 7 1.4 6.8 
11 0 0.0 0.0 1 6.7 9.1 1 9.1 11.1 4 0.9 5.1 6 1.2 5.8 
16 2 6.9 40.0 2 13.3 18.2 6 54.5 66.7 13 2.9 16.7 23 4.6 22.3 
18 1 3.4 20.0 1 6.7 9.1 1 9.1 11.1 7 1.6 9.0 10 2.0 9.7 
26 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 
31 1 3.4 20.0 1 6.7 9.1 0 0.0 0.0 3 0.7 3.8 5 1.0 4.9 
33 0 0.0 0.0 1 6.7 9.1 0 0.0 0.0 0 0.0 0.0 1 0.2 1.0 
35 1 3.4 20.0 1 6.7 9.1 1 9.1 11.1 7 1.6 9.0 10 2.0 9.7 
39 1 3.4 20.0 0 0.0 0.0 0 0.0 0.0 2 0.5 2.6 3 0.6 2.9 
42 0 0.0 0.0 3 20.0 27.3 2 18.2 22.2 3 0.7 3.8 8 1.6 7.8 
43 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 2 0.5 2.6 2 0.4 1.9 
44 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 4 0.9 5.1 4 0.8 3.9 
45 0 0.0 0.0 2 13.3 18.2 1 9.1 11.1 4 0.9 5.1 7 1.4 6.8 
51 1 3.4 20.0 1 6.7 9.1 2 18.2 22.2 5 1.1 6.4 9 1.8 8.7 
52 0 0.0 0.0 3 20.0 27.3 2 18.2 22.2 14 3.2 17.9 19 3.8 18.4 
53 0 0.0 0.0 1 6.7 9.1 1 9.1 11.1 3 0.7 3.8 5 1.0 4.9 
56 0 0.0 0.0 3 20.0 27.3 1 9.1 11.1 8 1.8 10.3 12 2.4 11.7 
58 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 2 0.5 2.6 2 0.4 1.9 
59 0 0.0 0.0 0 0.0 0.0 2 18.2 22.2 4 0.9 5.1 6 1.2 5.8 
66 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 12 2.7 15.4 12 2.4 11.7 
68 0 0.0 0.0 1 6.7 9.1 0 0.0 0.0 7 1.6 9.0 8 1.6 7.8 
70 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 3 0.7 3.8 3 0.6 2.9 
73 0 0.0 0.0 0 0.0 0.0 1 9.1 11.1 7 1.6 9.0 8 1.6 7.8 
82 0 0.0 0.0 0 0.0 0.0 1 9.1 11.1 3 0.7 3.8 4 0.8 3.9 
16 and/or 18 3 10.3 60.0 3 20.0 27.3 6 54.5 66.7 19 4.3 24.4 31 6.2 30.1 
Any HR-
HPV 5 17.2 100 11 73.3 100 9 81.8 100 78 17.6 100 103 20.7 100 
HC2+ No 
HR-HPV 1 3.4 - 2 13.3 - 1 9.1 - 18 4.1 - 22 4.4 - 
HC2 - 23 79.3 - 3 20.0 - 1 9.1 - 365 82.4 - 392 78.7 - 





  This study report describes the prevalence and 
distribution of HPV types within the general 
population in a Kenyan population.  The data 
represent a starting point for understanding the 
burden of HPV infections, which may help to 
assess the public health impact of HPV DNA 
genotyping in cervical cancer screening and 
HPV vaccination among Kenyan women. In our 
study sample the total HPV prevalence was 
21.3% in the general population.  Previous 
prevalence studies of HPV from selected 
populations have been documented at 14% and 
17% ([14], [13]).  Elsewhere in the world, the 
prevalence of HPV types from unselected 
population has been reported from previous 
studies as, 21% in Honduras, 7.6% in Costa 
Rica, and 16% in Thailand ([18], [19], [20].   
  In this study HPV 16 was the most prevalent 
(4.6%).  This is similar to what is documented 
world wide [8].  HPV 16 was not the sole 
predominant type in or study population.  The 
second most prevalent was HPV 52 (3.8%), 56 
and 66 (2.4%) and 18 and 35(2.0%).  HPV 52, 
56 and 66 were more prevalent than HPV 18.  
This is in contrast with most other studies 
conducted in both random and selected cervical 
cancer and pre cancer populations [8].  In 
general, however, HPV 52 is amongst the least 
prevalent HR HPV type exciting at rates of 0% 
in HPV positive women in Thailand, 6% in 
Philippines and 5% in Paraguay [21].   
  Available literature indicates that HR HPV 52 
has only been reported to be the most or second 
most prevalent in Nairobi 2003 and Thailand 
2000 respectively [22], [23].  It is important to 
note that we describe these comparisons with 
caution as we realize that these studies have used 
different HPV primers that can have different 
sensitivities for different HPV types.  Multiple 
types’ infection was common in our population 
with a prevalence of 37.7%. 
  There was a marked decline in the prevalence 
of HPV with age both overall and for each HR 
HPV type.  This is similar to other findings in 
Kenya and the region [22], [3].  This supports 
the fact that about 1 out of 4 women younger 
than 30 years of age have prevalent HPV 
infection [24]. 
  Most of the infections regress spontaneously 
due to natural immune responses that apparently 
develop during the normal course of these 
infections.  The rate of prevalent infections in 
women older than 30 years of age thus 
substantially decreases and ranges somewhere 
between 5 to 10% [24].  There was also a noted 
increase on HR HPV prevalence in women who 
tested positive for  any CIN than those who 
tested normal similar to what is documented 
world wide [25].   
  This study provides information on the cervical 
HPV types infecting a large number of Kenyan 
women.  We feel the women who participated in 
this study are a representative of those in other 
settings in Kenya and East Africa.  Therefore, 
the prevalence found reflects an estimate of HPV 
prevalence and distributions of specific HPV 
types within women in Kenya.  
 
Conclusion 
  The study demonstrates that HPV is highly 
prevalent in this region and confirms the findings 
of other African studies.  The data provided here 
may help to inform efforts to integrate HPV 
genotyping into cervical cancer screening and to 
develop vaccination strategies for this high risk 
population.  It is important to not that the 
distribution of HPV types varies substantially 
within regions and the importance of types 52, 
56, 66 and 35 has been demonstrated within this 
study.  Therefore, further epidemiological 
studies are warranted to identify predominant 
HPV types for sufficient development of 
efficient HPV vaccines for this region. 
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